4//SEC Filing
PERSEUSPUR LLC 4
Accession 0000950142-10-000387
CIK 0001401923other
Filed
Mar 7, 7:00 PM ET
Accepted
Mar 8, 8:47 PM ET
Size
22.1 KB
Accession
0000950142-10-000387
Insider Transaction Report
Form 4
PEARL FRANK H
10% Owner
Transactions
- Sale
Common Stock
2010-03-04$14.15/sh−677$9,580→ 2,868,472 total(indirect: See Footnotes) - Sale
Common Stock
2010-03-05$13.95/sh−4,616$64,393→ 2,842,887 total(indirect: See Footnotes) - Sale
Common Stock
2010-03-05$13.95/sh−97$1,353→ 2,842,887 total(indirect: See Footnotes) - Sale
Common Stock
2010-03-04$14.15/sh−14$198→ 2,868,472 total(indirect: See Footnotes) - Sale
Common Stock
2010-03-04$14.27/sh−10,553$150,591→ 2,868,472 total(indirect: See Footnotes) - Sale
Common Stock
2010-03-05$13.95/sh−20,872$291,164→ 2,842,887 total(indirect: See Footnotes) - Sale
Common Stock
2010-03-04$14.15/sh−3,061$43,313→ 2,868,472 total(indirect: See Footnotes)
PERSEUSPUR LLC
10% Owner
Transactions
- Sale
Common Stock
2010-03-04$14.15/sh−677$9,580→ 2,868,472 total(indirect: See Footnotes) - Sale
Common Stock
2010-03-04$14.27/sh−10,553$150,591→ 2,868,472 total(indirect: See Footnotes) - Sale
Common Stock
2010-03-05$13.95/sh−4,616$64,393→ 2,842,887 total(indirect: See Footnotes) - Sale
Common Stock
2010-03-05$13.95/sh−97$1,353→ 2,842,887 total(indirect: See Footnotes) - Sale
Common Stock
2010-03-04$14.15/sh−14$198→ 2,868,472 total(indirect: See Footnotes) - Sale
Common Stock
2010-03-05$13.95/sh−20,872$291,164→ 2,842,887 total(indirect: See Footnotes) - Sale
Common Stock
2010-03-04$14.15/sh−3,061$43,313→ 2,868,472 total(indirect: See Footnotes)
Footnotes (10)
- [F1]The price shown in Column 4 is a weighted average sale price. The price range for the sales is $14.00 to $14.23. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- [F10]Represents 20,872 shares of the Issuer's Common Stock sold by Biotech Management Partners. After the sale, Biotech Management Partners directly owns no shares of the Issuer's Common Stock.
- [F2]All of the securities reported herein are held for the account of Perseus-Soros BioPharmaceutical Fund, LP ("Perseus-Soros"), Perseus-Soros Partners, LLC ("Perseus-Soros Partners"), the general partner of Perseus-Soros, Perseus Biotech Investment, LLC ("PBI"), Perseus Biotech Fund Partners, LLC ("Perseus Biotech Fund Partners"), Biotech Management Partners, LLC ("Biotech Management Partners"), Perseus, L.L.C. ("Perseus"), Perseuspur, L.L.C. ("Perseuspur"), Perseus 2000 Biotech Satellite, LLC ("Perseus Satellite") and Frank H. Pearl. Perseus BioTech Fund Partners is a managing member of Perseus-Soros Partners and Biotech Management Partners. Perseuspur is the managing member of Perseus, PBI, Perseus Biotech Fund Partners and the entity that controls Perseus Satellite. Frank H. Pearl is the managing member of Perseuspur.
- [F3]Represents 677 shares of the Issuer's Common Stock sold by Perseus-Soros Partners. After the sale, Perseus-Soros Partners owned directly 4,616 shares of the Issuer's Common Stock.
- [F4]Represents 14 shares of the Issuer's Common Stock sold by PBI. After the sale, PBI owned directly 97 shares of the Issuer's Common Stock.
- [F5]Represents 3,061 shares of the Issuer's Common Stock sold by Biotech Management Partners. After the sale, Biotech Management Partners owned directly 20,872 shares of the Issuer's Common Stock.
- [F6]Represents 10,553 shares of the Issuer's Common Stock sold by Perseuspur. After the sale, Perseuspur owns directly 13,925 shares of the Issuer's Common Stock.
- [F7]The price shown in Column 4 is a weighted average sale price. The price range for the sales is $13.70 to $14.39. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price
- [F8]Represents 4,616 shares of the Issuer's Common Stock sold by Perseus-Soros Partners. After the sale, Perseus-Soros Partners directly owns no shares of the Issuer's Common Stock.
- [F9]Represents 97 shares of the Issuer's Common Stock sold by PBI. After the sale, PBI directly owns no shares of the Issuer's Common Stock.
Issuer
MAP Pharmaceuticals, Inc.
CIK 0001401923
Entity typeother
Related Parties
1- filerCIK 0001253323
Filing Metadata
- Form type
- 4
- Filed
- Mar 7, 7:00 PM ET
- Accepted
- Mar 8, 8:47 PM ET
- Size
- 22.1 KB